2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B1773AS4
    Sodium propionate-d5 202529-18-8 99.91%
    Sodium propionate-d5 is the deuterium labeled Propionate sodium (HY-B1773A). Sodium propionate is an orally active short-chain fatty acid. Sodium propionate can be produced by intestinal bacteria from the metabolism of dietary fiber. Sodium propionate increases PPAR-γ, inhibits NF-κB activation, and reduces COX-2 expression and NO production. Sodium propionate also induces Apoptosis and Autophagy. Sodium propionate reduces HSV-1-induced keratitis. Sodium propionate has anticancer effects against glioblastoma. Sodium propionate exhibits neuroprotective, antioxidant, and anti-inflammatory activities. Sodium propionate can be used in the research of spinal cord injury and Alzheimer's disease.
    Sodium propionate-d5
  • HY-B1773AS5
    Sodium propionate-d3 1210410-35-7 98.38%
    Sodium propionate-d3 is the deuterium labeled Propionate sodium (HY-B1773A). Sodium propionate is an orally active short-chain fatty acid. Sodium propionate can be produced by intestinal bacteria from the metabolism of dietary fiber. Sodium propionate increases PPAR-γ, inhibits NF-κB activation, and reduces COX-2 expression and NO production. Sodium propionate also induces Apoptosis and Autophagy. Sodium propionate reduces HSV-1-induced keratitis. Sodium propionate has anticancer effects against glioblastoma. Sodium propionate exhibits neuroprotective, antioxidant, and anti-inflammatory activities. Sodium propionate can be used in the research of spinal cord injury and Alzheimer's disease.
    Sodium propionate-d3
  • HY-W011954R
    Isopentyl 3-(4-methoxyphenyl)acrylate (Standard) 71617-10-2 99.18%
    Isopentyl 3-(4-methoxyphenyl)acrylate (Standard) is the analytical standard of Isopentyl 3-(4-methoxyphenyl)acrylate (HY-W011954). This product is intended for research and analytical applications. Isopentyl 3-(4-methoxyphenyl)acrylate, a derivative of cinnamon acid ester, is a UV-filter with anti-inflammatory activity.
    Isopentyl 3-(4-methoxyphenyl)acrylate (Standard)
  • HY-W015410R
    Disodium succinate (Standard) 150-90-3 98%
    Disodium succinate (Standard) is the analytical standard of Disodium succinate. This product is intended for research and analytical applications. Disodium succinate is an anti-anxiety agent with oral activity. Disodium succinate is the salt form of Succinic acid. Disodium succinate is an intermediate product of the tricarboxylic acid cycle. Disodium succinate is an important platform chemical. Disodium succinate can be used as surfactant, additive, ion chelating agent, flavoring agent and other applications in chemical, pharmaceutical and food fields.
    Disodium succinate (Standard)
  • HY-W015515R
    L-Citronellol (Standard) 7540-51-4 99.53%
    L-Citronellol ((S)-3,7-Dimethyloct-6-en-1-ol) is an analytical standard for L-Citronellol (HY-W015515). This product is intended for research and analytical applications. L-Citronellol is a natural product with anti-allergic and neuroprotective effects. L-Citronellol inhibits mast cell activation and the release of inflammatory factors by inhibiting the ERK pathway. L-Citronellol inhibits BACE1/PSEN1 and AChE, reduces TNF-α expression and lipid peroxidation, demonstrating the potential of multi-target anti-Alzheimer's disease (AD).
    L-Citronellol (Standard)
  • HY-W015600R
    2-Acetamidophenol (Standard) 614-80-2 99.45%
    2-Acetamidophenol (Standard) is the analytical standard of 2-Acetamidophenol. This product is intended for research and analytical applications. 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation.
    2-Acetamidophenol (Standard)
  • HY-W094747A
    Benzalazine 588-68-1 98.82%
    Benzalazine is a 5-azo derivative of 5-Aminosalicylic Acid (HY-15027) that can be used for the research of ulcerative colitis and Crohn's disease of the large intestine. The benzalazine metabolite 5-ASA and the 5-ASA metabolite acetyl-5-aminosalicylic acid are excreted mainly with the faeces.
    Benzalazine
  • HY-W109812S
    Sinapyl alcohol-d3 934634-29-4
    Sinapyl alcohol-d3 is the deuterated labeled Sinapyl alcohol (HY-W109812). Sinapyl alcohol is an orally active anti-inflammatory and antinociceptive agent. Sinapyl alcohol reduces the expression level of inducible NO synthase and COX-2.
    Sinapyl alcohol-d3
  • HY-W010255AS
    Phenylglyoxylic acid-d5sodium 2708283-39-8 99.79%
    Phenylglyoxylic acid-d5 (Benzoylformic acid-d5) sodium is the deuterium labeled Phenylglyoxylic acid sodium (HY-W010255A). Phenylglyoxylic acid (Benzoylformic acid) is a metabolite of ethylbenzene and styrene (EB/S) and can be used as a biomarker of exposure to EB/S in human. Phenylglyoxylic acid can be used as drug intermediate for synthesis of antineoplastic compounds.
    Phenylglyoxylic acid-d5sodium
  • HY-W017443S2
    L-Asparagine-13C4,15N2,d3 monohydrate 2483829-30-5 99.90%
    L-Asparagine-13C4,15N2,d3 monohydrate is the deuterium, 13C-, and 15N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
    L-Asparagine-13C4,15N2,d3 monohydrate
  • HY-W018772S10
    D-Ribose-5,5-C-d2 478506-32-0 98.0%
    D-Ribose-d2 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl
    D-Ribose-5,5-C-d2
  • HY-117726
    WAY-169916 669764-18-5 99.32%
    WAY-169916 is a pathway-selective ligand of ER (estrogen receptor) that acts by inhibiting NF-kB transcriptional activity. WAY-169916 has potent anti-inflammatory effect.
    WAY-169916
  • HY-112870AS
    Firmonertinib-d3 mesylate
    Firmonertinib-d3 (Alflutinib-d3) mesylate is the deuterium labeled Firmonertinib mesylate (HY-112870A). Firmonertinib (Alflutinib; Furmonertinib) mesylate is is an orally active, mutant-selective, and blood-brain barrier penetrant EGFR inhibitor. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib mesylate has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation.
    Firmonertinib-d3 mesylate
  • HY-16734
    Amiselimod 942399-20-4 98%
    Amiselimod (MT-1303) is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimodis promising for research of autoimmune diseases.
    Amiselimod
  • HY-22252
    4-Aminosalicylic acid hemicalcium 133-15-3 98%
    4-Aminosalicylic acid hemicalcium is an inhibitor for dihydrofolate reductase (DHFR) and an antituberculous agent. 4-Aminosalicylic acid hemicalcium exhibits anti-inflammatory activity and can be used in research of inflammatory bowel disease (IBD). 4-Aminosalicylic acid hemicalcium is orally active.
    4-Aminosalicylic acid hemicalcium
  • HY-101098
    PD-1-IN-18 1673534-97-8 98%
    PD-1-IN-18 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator.
    PD-1-IN-18
  • HY-10182C
    Laduviglusib dihydrochloride 2109414-84-6 98%
    Laduviglusib dihydrochloride (CHIR-99021 dihydrochloride; CT99021 dihydrochloride) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib dihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib dihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib dihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib dihydrochloride induces autophagy.
    Laduviglusib dihydrochloride
  • HY-129388
    Pulrodemstat Methylbenzenesulfonate 2097523-57-2 98%
    Pulrodemstat (CC-90011) Methylbenzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. Pulrodemstat Methylbenzenesulfonate is less enzymatic inhibition against LSD2, MAO-A, and MAO-B. Pulrodemstat Methylbenzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity.
    Pulrodemstat Methylbenzenesulfonate
  • HY-136527
    BMS-986251 2460133-35-9 98%
    BMS-986251 is an orally active and selective RORγt inverse agonist with an EC50 of 12 nM for RORγt GAL4. BMS-986251 inhibits IL-17 with an EC50 of 24 nM in human whole blood assay. BMS-986251 demonstrates robust efficacy in mouse acanthosis and Imiquimod-induced (HY-B0180) models (preclinical models of psoriasis).
    BMS-986251
  • HY-142296
    RORγt inhibitor 1 1561770-72-6 98%
    RORγt inhibitor 1 is a RORγt allosteric inhibitor with an IC50 value of 1 nM.
    RORγt inhibitor 1
Cat. No. Product Name / Synonyms Application Reactivity